Sai Life Sciences Announces Major Recruitment Drive for 200 Scientists

Sai Life Sciences Limited , a leading Contract Research, Development & Manufacturing Organization (CRDMO), has unveiled plans for a significant expansion of its scientific workforce. The company aims to recruit 200 scientists in November 2025 to meet the growing demand for its Discovery and CMC services.

Recruitment Details

Aspect	Details
Date	November 15-16, 2025
Time	9:00 a.m. to 5:00 p.m.
Location	Sai Vishram Business Hotel, Hebbagodi, Bengaluru
Interview Type	Walk-in

Open Positions and Qualifications

The company is seeking candidates across various scientific functions:

Process R&D
Analytical R&D
Process Engineering
Biology (in vitro and in vivo)
DMPK

Desired qualifications include:

M.Sc. in Organic Chemistry, Life Sciences, Microbiology, Biochemistry, or Biotechnology
M.Pharm in Pharmacology or related disciplines
B.E. / M.E. in Chemical Engineering
Ph.D. in relevant areas

Sai Life Sciences is looking for professionals with 2-14 years of experience in these fields.

Company Expansion and Growth

This recruitment drive is part of Sai Life Sciences' broader expansion strategy. The company has recently announced several growth initiatives:

A new CMC Process R&D Center at its Hyderabad campus, set to be completed by September 2026. This facility will:
- Double the company's Process R&D capacity
- Add new capabilities in peptide development, oligo intermediates & linkers development, formulation development, and early-phase clinical supplies
Launch of a state-of-the-art biology facility at the Hyderabad campus, enhancing the company's Integrated Discovery platform

Siva Chittor, Whole-Time Director and Chief Financial Officer of Sai Life Sciences, emphasized the company's commitment to creating an environment where scientists can excel. He stated, "At Sai, we are continuously building an ecosystem where scientists can do the best work of their careers — solving complex scientific challenges that make a real difference to patients' lives."

Company Overview

Sai Life Sciences has established itself as a significant player in the pharmaceutical and biotech industry:

Partners with over 300 global innovators, including 18 of the top 20 pharmaceutical companies
Employs a team of more than 3,400 professionals
Operates across India, the UK, and the US
Focuses on accelerating the discovery, development, and commercialization of complex small molecules and emerging modalities

The company's expansion and recruitment efforts underscore its commitment to advancing scientific frontiers and delivering innovative solutions to bring new medicines to patients worldwide.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.83%	-1.10%	-5.16%	+19.58%	+14.39%	+14.39%

Sai Life Sciences Limited , a leading Contract Research, Development and Manufacturing Services (CRDMO) provider, has announced its financial results for the second quarter, showcasing a remarkable improvement in both revenue and profitability.

Strong Financial Performance

The company reported a consolidated net profit of 838.44 million rupees for Q2, representing a significant increase from 415.10 million rupees in the same quarter last year. This translates to a year-on-year growth of approximately 102%, effectively doubling the company's bottom line.

Revenue from operations also saw substantial growth, rising to 5,374.70 million rupees compared to 3,955.62 million rupees in the corresponding quarter of the previous year, marking an increase of about 35.9%.

Key Financial Metrics

Here's a breakdown of the key financial metrics for Q2:

Metric	Current Q2 (in million rupees)	Previous Q2 (in million rupees)	YoY Change
Revenue from Operations	5,374.70	3,955.62	+35.9%
Net Profit	838.44	415.10	+102.0%
Total Income	5,527.95	4,055.15	+36.3%

Operational Highlights

The company's strong performance can be attributed to its focus on providing high-quality CRDMO services. The significant increase in revenue suggests growing demand for Sai Life Sciences' offerings in the pharmaceutical and biotechnology sectors.

Looking Ahead

As Sai Life Sciences continues to demonstrate strong financial performance, investors and industry observers may be watching closely to see if this growth trajectory can be maintained in the coming quarters. The company's ability to capitalize on opportunities in the evolving pharmaceutical research and manufacturing landscape will be crucial for its future success.

Sai Life Sciences' impressive Q2 results underscore its growing prominence in the CRDMO sector and may position the company favorably for future growth and expansion opportunities.